Pricing Log in Create free account
Friday 6 November 2026 Export MRVI’s income statement to Excel — free account

Maravai LifeSciences Holdings, Inc.

MRVI Healthcare Biotechnology

Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.

Revenue
+10.1%
EPS
+50.0%
Free cash flow
+123.9%
Total debt
−45.4%

Quarter to September 2026, against a year earlier

7.52 0.54 +7.74%
Market cap
$1.8B
P/E
0.0×
Fwd P/E
−24.4×
Dividend yield
—
F-score
2/9
Altman Z
0.44
Beneish M
−3.30
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.37
Sold, $m 0.25
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy 1 — — — — — — — — — — —
Sell — — — — — — 1 — — — — —
Insider Ownership 25.35%

Capital & Financial Ratios $m

Size
Market Cap 1,810.00
Revenue ttm 213.00
Net income ttm (115.02)
Free cash flow ttm (12.54)
Net debt Q 103.45
Valuation
P/E 0.00
Forward P/E (24.40) (negative: loss-making)
Price / sales 5.26
Forward P/S Powerpack
Price / FCF 0.00
Price / book 3.30
Financial health
Current ratio Q 4.66 (at or above 1.5: strong)
Debt / equity Q 0.52
Interest coverage Q (5.12)
Growth
Revenue growth Q +10.14% (above 0%: growing)
Operating income growth Q +49.75% (above 0%: growing)
EPS, this year +72.33% (at or above 15%: strong)
EPS, next year A +2.58%
Revenue, next year A +14.03% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +41.09% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.7×, against a ten-year median of 3.5×; over the ten years it ranged from 1.4× in 2025 to 33.9× in 2020.
P/S against its own 10 years 81.43%
10-year low 10-year high
P/B against its own 10 years 67.40%
10-year low 10-year high
EV/Sales against its own 10 years 80.83%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 575 322 217 73
Receivables 55 39 25 26
Inventory 51 50 40 43
Other — — — —
700 429 296 154
2023 2024 2025 Q'26
Payables 11 12 3 6
ST’ Debt 5 5 5 2
Other — — — —
87 57 45 33

Compound Annual Growth %

10y 5y 3y
Sales — (8.15%) (40.53%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 19.22% (25.61%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.05 Actual −0.03

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.07 −0.04 Beat by 0.03
Q1 FY26 −0.05 0.01 Beat by 0.06
Q2 FY26 −0.05 −0.02 Beat by 0.03
Q3 FY26 −0.05 −0.03 Beat by 0.02
Q4 FY26 −0.04 — Reports 24 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.02) (0.08) (0.09) — —
’25 (0.21) (0.27) (0.18) (0.24) (0.90)
’24 (0.09) (0.05) (0.70) (0.18) (1.05)
’23 0.00 (0.05) (0.05) (0.80) (0.90)
’22 0.50 0.53 0.34 0.28 1.67
’21 0.24 0.44 0.23 0.42 1.56
’20 0.09 0.01 0.15 0.13 2.36
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 66 51 46 — —
’25 47 47 42 50 186
’24 64 69 69 57 259
’23 79 69 67 74 289
’22 244 243 191 205 883
’21 148 218 205 228 799
’20 51 47 88 98 284
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 9 4 5 — —
’25 (9) (10) (15) (23) (58)
’24 (8) 17 13 (15) 7
’23 85 19 14 8 126
’22 162 164 110 99 536
’21 38 166 106 59 369
’20 10 12 51 79 152
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 4 4 4 — —
’25 (14) (13) (19) (25) (71)
’24 (14) 8 5 (20) (22)
’23 77 (6) (2) (9) 61
’22 160 163 104 93 519
’21 36 161 104 53 354
’20 41 9 41 71 161
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.9
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — 124 143 284 799 883 289 259 186 213 +6.0% 212 225 244 +9.5%
Gross margin, % — — 50.93 53.30 71.96 82.41 80.87 48.52 41.79 18.30 39.15 (32.6) pt
EBT — — (16) (6) 82 531 551 618 (261) (235) (115) +46.1%
EBT margin, % — — (13.32) (4.09) 28.76 66.41 62.45 213.79 (100.89) (126.50) (54.19) (113.2) pt
Net income — 0 (17) (5) 79 469 491 (138) (260) (231) (115) n/m
Per share, $
Per share, $ Revenue — — 0.49 0.56 27.45 6.96 6.71 2.19 1.88 1.29 1.43 +14.9%
Earnings — — (0.07) (0.02) 7.43 1.59 1.67 (0.90) (1.05) (0.90) (0.43) +45.1%
Cash flow — — 0.00 0.10 14.70 3.21 4.07 0.96 0.05 (0.40) (0.03) +147.6%
Capex — — (0.01) (0.07) 0.88 (0.12) (0.13) (0.50) (0.22) (0.09) (0.05) +30.4%
Free cash flow — — (0.01) 0.03 15.58 3.09 3.94 0.46 (0.16) (0.49) (0.08) +64.5%
Book value — — 0.58 0.57 14.95 4.75 6.88 5.99 4.19 2.58 2.28 +23.7%
Shares, m — — 254 254 10 115 132 132 138 144 147 (7.8%)
Valuation, ×
Valuation, × P/E — — 162.76 162.76 32.87 26.86 8.20 0.00 0.00 0.00 0.00 49.2
P/S — — 34.19 34.19 3.99 6.02 2.04 3.08 2.90 2.53 5.26 11.1
P/B — — 52.41 52.41 7.33 8.82 1.99 1.13 1.30 1.26 3.30 15.8
EV/Sales — — 35.84 35.84 5.24 5.99 1.92 3.01 2.92 3.09 5.75 11.7
EV/FCF — — 81.35 81.35 9.23 13.52 3.27 14.34 (34.07) (8.12) (97.64) 20.1
Cash, $m
Cash, $m Operating cash flow — — 0 24 152 369 536 126 7 (58) (5) +126.9%
Capex — — (4) (17) 9 (14) (17) (66) (30) (13) (7) +20.3%
Free cash flow — — (4) 7 161 354 519 61 (22) (71) (13) +51.9%
Balance, $m
Balance, $m Working capital — — 18 31 201 646 738 612 372 251 121 +45.9%
Net debt — — 318 366 355 (21) (105) (19) 5 105 103 (14.6%)
Shareholders’ equity — — 148 145 155 545 905 790 577 373 340 +14.1%
Returns, %
Returns, % ROA — — (1.66) (0.80) 8.32 11.42 10.48 (6.31) (11.61) (14.70) (9.06) (13.0) pt
ROIC — — 2.20 2.94 14.71 66.07 44.83 (2.57) (25.31) (28.16) (13.62) (30.4) pt
ROE — — (3.14) (3.05) 51.37 52.00 30.36 (14.04) (21.19) (27.53) (17.01) (24.4) pt
People
People Employees — — — 390 58 470 610 650 570 435 — +1.8%
Revenue/emp, $m — — 0.00 0.37 4.90 1.70 1.45 0.44 0.45 0.43 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Maravai LifeSciences Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
COAG Hemab Therapeutics Holdings, Inc. $2.1B — (loss-making) — — n/m — — 0.00% Compare
FTRE Fortrea Holdings Inc. $2.0B — (loss-making) — (loss-making) −1.40% (below 0%: shrinking) n/m −33.96% (below 0%: shrinking) 20.17% 2.17% Compare
TRAX First Tracks Biotherapeutics, Inc. $1.9B — (loss-making) — — n/m +55.91% (above 0%: growing) — 0.00% Compare
REPL Replimune Group, Inc. $1.9B — (loss-making) — — n/m +42.22% (above 0%: growing) 0.00% 0.00% Compare
HRMY Harmony Biosciences Holdings, Inc. $1.9B 10.5× 9.9× +12.30% (above 0%: growing) −6.24% (below 0%: shrinking) −29.42% (below 0%: shrinking) 70.00% 20.15% Compare
SRPT Sarepta Therapeutics, Inc. $1.9B — (loss-making) 6.3× −4.51% (below 0%: shrinking) n/m +231.84% (above 0%: growing) 0.00% (2.37%) Compare
VIR Vir Biotechnology, Inc. $1.9B — (loss-making) — (loss-making) +19,582.54% (above 0%: growing) n/m +200.47% (above 0%: growing) 100.00% 30.75% Compare
TRVI Trevi Therapeutics, Inc. $1.8B — (loss-making) — — n/m −73.77% (below 0%: shrinking) 0.00% 0.00% Compare
MRVI Maravai LifeSciences Holdings, Inc. $1.8B — (loss-making) — (loss-making) +10.14% (above 0%: growing) n/m +123.88% (above 0%: growing) 35.31% (44.97%)
Median of peers $1.9B — — +5.45% — +42.22% 10.09% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 24 April 2026

Ownership

Directors and executive officers, together 1.42%
GTCR 50.68%
Stuart FeldmanHudson View Holdings LLCHudson View Capital LLCJD Squared Holdings II LLCJD Squared Capital II LLCMatthew BarkoffJoshua Wool 4.06%
12 West Capital Management LP 3.46%
BlackRock, Inc. 3.32%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Maravai LifeSciences Holdings, Inc. (MRVI) Latest News

6 Nov

Impact 3 · · Simply Wall St.

5 Nov

Impact 3 · · The Motley Fool transcript

4 Nov

Impact 3 · · MarketBeat
Impact 3 · · Business Wire

27 Oct

Impact 4 · · Simply Wall St.

17 Oct

Impact 4 · · Simply Wall St.

4 Oct

Impact 4 · · Insider Monkey

29 Sep

Impact 4 · · Business Wire

25 Sep

Impact 4 ·

24 Sep

Impact 3 · · Simply Wall St.

13 Aug

Impact 4 · · The Motley Fool transcript

7 Aug

Impact 3 · · Moby transcript
Impact 3 · · MarketBeat

6 Aug

Impact 3 ·
Impact 3 ·

20 Jul

Impact 3 ·

16 Jun

Impact 3 ·

3 Jun

Impact 3 · · Business Wire

14 May

Impact 4 · · Simply Wall St.

9 May

Impact 4 · · The Motley Fool transcript

8 May

Impact 4 · · Moby
Impact 4 · · MarketBeat

7 May

Impact 4 · · Zacks
Impact 4 · · Business Wire

6 May

Impact 3 · · Zacks

13 Apr

Impact 3 · · Simply Wall St.

29 Mar

Impact 3 · · Simply Wall St.

26 Feb

Impact 4 · · Moby
Impact 4 · · MarketBeat

25 Feb

Impact 3 · · Zacks

MRVI metrics, ten years each

stockrow.com/MRVI · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com